Highlights of the 27th international papillomavirus conference and clinical workshop: Part 1

Future Virology

Volumn 6, Issue 12, 2011, Pages 1389-1396

  Arbyn, Marc ^c   Gissmann, Lutz ^a   Schneider, Achim ^b   Kaufmann, Andreas M ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

biomarker; carcinogenesis; genomics; HPV; human papillomavirus; immunology; prophylactic vaccine; therapeutic vaccine

Indexed keywords

CIDOFOVIR; FANCONI ANEMIA GROUP D2 PROTEIN; GP 96 VACCINE; IPILIMUMAB; LOPINAVIR; MONOCLONAL ANTIBODY; MONTANIDE ISA 51; PROVENGE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN; WART VIRUS VACCINE;

BREAST CANCER; CANCER PREVENTION; CANCER STEM CELL; CARCINOGENESIS; CELLULAR IMMUNITY; CONFERENCE PAPER; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; INFECTION PREVENTION; LIFE CYCLE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GENE; TUMOR IMMUNOLOGY; VERRUCA VULGARIS; WART VIRUS;

EID: 82455167316     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.126     Document Type: Conference Paper

References (12)

1. IARC Monograph Working Group; zur Hausen H, Arbyn M, Villa L et al. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. IARC Press, France (2007).
2. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24(Suppl. 3), S11-S25 (2006).
3. Kjaer SK, Tran TN, Sparen P et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J. Infect. Dis. 196, 1447-1454 (2007).
4. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915-1927 (2007).
5. Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301-314 (2009).
6. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl. 3), S78-S89 (2006).
7. Cuzick J, Arbyn M, Ronco G et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl. 10), K29-K41 (2008).
8. Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364, 401-411 (2011).
9. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11, 781-789 (2010).
10. van de Nieuwenhof HP, van Kempen LC, de Hullu JA et al. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol. Biomarkers Prev. 18, 2061-2067 (2009).
11. Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 29(48), 9112-9122 (2011).
12. Arbyn M, Steben M. Highlights of the 26th International Papillomavirus Conference and Workshops (Montreal, 3-8 July 2010).Future Oncol. 6, 1711-1724 (2010).